EU/3/15/1435: Orphan designation for the treatment of systemic sclerosis
Nitroglycerin
Table of contents
Overview
On 12 February 2015, orphan designation (EU/3/15/1435) was granted by the European Commission to Covis Pharma S.à.r.l., Luxemburg, for nitroglycerin for the treatment of systemic sclerosis.
Key facts
Active substance |
Nitroglycerin
|
Intended use |
Treatment of systemic sclerosis
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/15/1435
|
Date of designation |
12/02/2015
|
Sponsor |
Covis Pharma S.à.r.l.
Atrium Business Park 33 rue du Puits Romains - Boite 6 L - 8070 Bertrange Luxembourg Tel. +35 228 2651 E-mail: regulatory@covispharma.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: